cGMP causes smooth muscle relaxation, which permits more blood flow into the penis, allowing for an erection. When sexually stimulated, nitric oxide is released locally, which increases cyclic guanosine monophosphate (cGMP). Phosphodiesterase type 5 (PDE-5) inhibitors are considered the first line and the mainstay treatment for ED. Stress, anxiety, and depression can also psychologically affect a man’s ability to get an erection. The antihypertensive drugs designed to lower blood pressure in those patients can also contribute to reducing blood flow to the penis.ĮD can also be associated with diabetes, obesity, smoking, and excessive alcohol consumption.
This can be caused by a multitude of reasons, but we most often see this issue arise commonly in patients who suffer from hypertension and atherosclerosis. The most common cause of ED is when blood flow to the penis is reduced. Many of the medications used in the treatment of ED have interactions with other medications, so it is crucial for pharmacists to carefully examine patient profiles to optimize therapy and ensure safety. It is important to note that because the prevalence of ED increases with age, it is common for those affected to have other comorbidities or treatment regimens.
Although not a deadly condition, it often has a drastic effect on a person’s quality of life, leading many men with ED to seek treatment.
An estimated 30 to 50 million men in the United States have erectile dysfunction (ED), a condition defined by an inability to achieve or maintain an erection firm enough for sexual intercourse.
0 kommentar(er)
